Speaker: Dan White, Quintiles, Vice President, Global Operations for Quintiles
With support from the FDA and EMA, the industry is ready to realize the promise of risk-based monitoring. Quintiles has been using elements of RBM since 2001 as a smarter, more efficient approach to clinical trial execution that focuses on critical data. In this webinar, Quintiles will share recent research insights and real experiences using a modernized approach to risk-based monitoring. By integrating best practices from RBM studies with new approaches and innovative technology, we will share common challenges, lessons learned, and how to best apply processes and technology to deliver the optimal outcome for a study.